XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.23.2

Collaboration and License Agreement - Additional Information (Details) $ in Thousands, ¥ in Millions |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 7 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 31, 2021 USD ($) | Oct. 31, 2021 JPY (¥) | Jan. 01, 2019 USD ($) | Jan. 01, 2019 JPY (¥) | Dec. 31, 2022 USD ($) | Dec. 31, 2022 JPY (¥) | Jul. 31, 2022 | Oct. 31, 2021 | Jun. 30, 2020 USD ($) | May 30, 2020 | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Jul. 31, 2023 | Jun. 30, 2023 JPY (¥) | Mar. 31, 2023 USD ($) | Feb. 28, 2023 USD ($) | May 31, 2020 USD ($)
Roche |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable payment received |  |  |  |  |  |  |  |  |  |  | $ 138,626 |  | $ 138,626 |  |  |  |  |  |
Roche | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated period of completion of trials to get revenue |  |  |  |  |  |  | 24 months |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable payment received |  |  |  |  |  |  |  |  |  |  | 134,600 |  | 134,600 |  |  |  |  |  |
Deferred revenue recognized |  |  |  |  |  |  |  |  |  |  | 4,800 | $ 0 | 10,100 | $ 0 |  |  |  |  |
Deferred revenue |  |  |  |  | $ 18,000 |  |  |  |  |  | 11,800 |  | 11,800 |  |  |  |  |  |
Deferred revenue, current |  |  |  |  | 15,300 |  |  |  |  |  | 11,100 |  | 11,100 |  |  |  |  |  |
Deferred revenue, noncurrent |  |  |  |  | 2,700 |  |  |  |  |  | 700 |  | 700 |  |  |  |  |  |
Roche | Collaboration and License Agreement | Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones Payments |  |  |  |  |  |  |  |  |  |  |  |  | 1,172,000 |  |  |  |  |  |
Roche | Collaboration and License Agreement | Clinical trial materials |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable payment received |  |  |  |  |  |  |  |  |  |  | 5,600 |  | 5,600 |  |  |  |  |  |
Roche | Collaboration and License Agreement | Product additional clinical development plan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000 |
Non-refundable payment received |  |  |  |  |  |  |  |  |  |  | 4,000 |  | 4,000 |  |  |  |  |  |
Amount of additional consideration |  |  |  |  |  |  |  |  |  |  | 4,000 |  | 4,000 |  |  |  |  |  |
Roche | Collaboration and License Agreement | Upfront non refundable first payment received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable payment received |  |  |  |  |  |  |  |  |  |  | 125,000 |  | 125,000 |  |  |  |  |  |
Bristol-Myers Squibb Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable payment received |  |  |  |  |  |  |  |  |  |  | 50,000 |  | 50,000 |  |  |  |  |  |
Bristol-Myers Squibb Company | Druggable Target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue recognized |  |  |  |  |  |  |  |  |  |  | 12,700 | 0 | 12,700 | 0 |  |  |  |  |
Bristol-Myers Squibb Company | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration term expiration period |  |  |  |  |  |  |  |  |  | 42 months |  |  |  |  |  |  |  |  |
Initial nonrefundable upfront fee received |  |  |  |  |  |  |  |  | $ 50,000 |  |  |  |  |  |  |  |  |  |
Non-refundable payment received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000
Deferred revenue |  |  |  |  | 27,354 |  |  |  |  |  | 13,287 |  | 13,287 |  |  |  | $ 26,988 |  |
Deferred revenue, current |  |  |  |  | 27,400 |  |  |  |  |  | 13,287 |  | 13,287 |  |  |  |  |  |
Deferred revenue, noncurrent |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |  |  |
Bristol-Myers Squibb Company | Collaboration and License Agreement | Product Research Activity [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue recognized |  |  |  |  |  |  |  |  |  |  | 1,200 | 700 | 1,600 | 1,100 |  |  |  |  |
Bristol-Myers Squibb Company | Collaboration and License Agreement | Druggable Target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, triggered furthur development |  |  |  |  |  |  |  |  |  |  | 1,000 | 0 | 1,000 | 0 |  |  |  |  |
Option fee |  |  |  |  |  |  |  |  |  |  | 250 |  | 250 |  |  |  |  |  |
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments entitled to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 301,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments entitled to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 176,000
Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum | Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments entitled to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 125,000
Ono Pharmaceutical Company Ltd | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial nonrefundable upfront fee received |  |  | $ 8,100 | ¥ 900 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration term extended period |  |  |  |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |
Second amendment agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  | In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023 |  |  |  |
Milestone payments entitled to be received |  |  |  |  |  |  |  |  |  |  | 6,500 |  | 6,500 |  |  | ¥ 750 |  |  |
Deferred Revenue, Additions | $ 900 | ¥ 100 |  |  | $ 1,500 | ¥ 200 |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue recognized |  |  |  |  |  |  |  |  |  |  | 10,500 | $ 0 | 10,500 | $ 0 |  |  |  |  |
Ono Pharmaceutical Company Ltd | Collaboration and License Agreement | Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments entitled to be received |  |  |  |  |  |  |  |  |  |  | $ 149,500 |  | $ 149,500 |  |  | ¥ 17,210 |  |  |

X
- Definition Additional consideration contract with customer liability. + References No definition available. + Details
Name: | rptx_AdditionalConsiderationContractWithCustomerLiability
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amoun t of collaboration revenue receivable + References No definition available. + Details
Name: | rptx_CollaborationRevenueReceivable
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration term expiration period. + References No definition available. + Details
Name: | rptx_CollaborationTermExpirationPeriod
Namespace Prefix: | rptx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration term extended period. + References No definition available. + Details
Name: | rptx_CollaborationTermExtendedPeriod
Namespace Prefix: | rptx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Deferred revenue triggered furthur development. + References No definition available. + Details
Name: | rptx_DeferredRevenueTriggeredFurthurDevelopment
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Estimated period of completion of trials to get revenue. + References No definition available. + Details
Name: | rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue
Namespace Prefix: | rptx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestones payments. + References No definition available. + Details
Name: | rptx_MilestonesPayments
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option fee. + References No definition available. + Details
Name: | rptx_OptionFee
Namespace Prefix: | rptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Second amendment agreement. + References No definition available. + Details
Name: | rptx_SecondAmendmentAgreement
Namespace Prefix: | rptx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rptx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_ClinicalTrialMaterialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_AdditionalClinicalDevelopmentPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_UpfrontNonRefundableFirstPaymentReceivedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_DruggableTargetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_ProductResearchActivityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rptx_ResearchDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |